Clinical oncology最新文献

{"title":"Aggressive NK-Cell Leukemia in Western Populations: A Population-Based Study","authors":"P. Loap, Y. Kirova","doi":"10.1016/j.clon.2025.103880","DOIUrl":"10.1016/j.clon.2025.103880","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"44 ","pages":"Article 103880"},"PeriodicalIF":3.2,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144231824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Elective Neck Irradiation and Severe Lymphopenia in Patients Treated With Head and Neck Chemoradiotherapy","authors":"T.A. Mickel ,&nbsp;D.H. Moon ,&nbsp;V. Avkshtol ,&nbsp;N.-L. Pham ,&nbsp;J.L. Shah ,&nbsp;R.S. Hughes ,&nbsp;B.D. Sumer ,&nbsp;D.J. Sher","doi":"10.1016/j.clon.2025.103873","DOIUrl":"10.1016/j.clon.2025.103873","url":null,"abstract":"<div><h3>Introduction</h3><div>Lymphopenia is a complication of head and neck radiotherapy, but its specific drivers are not well understood. We analyzed relationships between the extent of elective nodal irradiation (ENI) and severe lymphopenia (SL, grade 4) in patients treated with chemoradiotherapy (CRT) for head and neck squamous-cell carcinoma (HNSCC).</div></div><div><h3>Methods</h3><div>We included patients with new T1-4N0-3M0 HNSCC of the oropharynx, larynx, and hypopharynx who were treated with definitive CRT between 2017 and 2021 on either two prospective phase II ENI de-escalation trials (INFIELD, INRT-AIR) or with standard-of-care (SOC) CRT. We recorded absolute lymphocyte count before and up to 1–2 years after treatment. Differences in SL were compared between cohorts, and relationships between the carotid artery (CA) and cervical spine (CS) dose, SL, and locoregional progression-free, distant metastasis-free, and overall survival (LRPFS, DMFS, OS) were investigated.</div></div><div><h3>Results</h3><div>A total of 169 patients from INFIELD (N = 57), INRT-AIR (N = 61), and SOC (N = 51) were included. The SL incidence increased with increasing ENI dose: 1.6%, 16% and 35% in the INRT-AIR, INFIELD and SOC cohorts, respectively (p &lt; 0.001). On multivariate analysis, higher mean dose to the contralateral CA (OR 9.0, 95% CI 1.9–43.7) and CS (OR 5.1, 95% CI 1.04–25.2) was associated with SL. Cox regression showed independent relationships between CS dose and OS (HR 2.96, 95% CI 1.38–6.3) and DMFS (HR 2.72, 95% CI 1.34–5.51).</div></div><div><h3>Conclusions</h3><div>ENI de-escalation resulted in significantly less SL, and we identified novel predictors of this toxicity. Mitigating RT-induced SL may play a role in combining RT with immunotherapy in the definitive setting.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"44 ","pages":"Article 103873"},"PeriodicalIF":3.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144243231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Stereotactic Ablative Body Radiotherapy for Renal Cell Carcinoma With Thrombus: Do or Do Not?","authors":"J. Le Guévelou ,&nbsp;K. Bensalah ,&nbsp;L. Albiges ,&nbsp;S. Siva ,&nbsp;P. Sargos","doi":"10.1016/j.clon.2025.103871","DOIUrl":"10.1016/j.clon.2025.103871","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"44 ","pages":"Article 103871"},"PeriodicalIF":3.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144281102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regarding “Neuroendocrine Deficits and Weight Development Before and After Proton Therapy in Children With Craniopharyngioma” by Bischoff et al.","authors":"S. Li ,&nbsp;J. Wang","doi":"10.1016/j.clon.2025.103874","DOIUrl":"10.1016/j.clon.2025.103874","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"44 ","pages":"Article 103874"},"PeriodicalIF":3.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144242619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Clinical and Neurological Alterations Before Radiation Therapy in Children With Malignant Brain Tumours","authors":"M. Lecchi ,&nbsp;A. Erbetta ,&nbsp;P. Grampa ,&nbsp;C. Cavatorta ,&nbsp;S. Meroni ,&nbsp;A. Nigri ,&nbsp;F. Spreafico ,&nbsp;E. Pecori ,&nbsp;M.C. Oprandi ,&nbsp;V. Biassoni ,&nbsp;E. Schiavello ,&nbsp;D. Peruzzo ,&nbsp;R. Laureanti ,&nbsp;L. Mainardi ,&nbsp;S. Vennarini ,&nbsp;G. Poggi ,&nbsp;O. Nigro ,&nbsp;P. Verderio ,&nbsp;E. Pignoli ,&nbsp;M. Massimino","doi":"10.1016/j.clon.2025.103872","DOIUrl":"10.1016/j.clon.2025.103872","url":null,"abstract":"<div><h3>Aim</h3><div>Young patients with a brain tumour (BT) show neurocognitive alterations as both consequences of the tumour and of the treatments received. In this paper we present the basal analysis of a patient’s series, correlating tumour localisation, symptoms, neurological/endocrinological impairments, surgery/ies ± chemotherapy, and cognitive assessments at the time of enrolment before focal-radiotherapy (RT).</div></div><div><h3>Methods</h3><div>Sixty-six children eligible for focal RT underwent a neurocognitive assessment. The demographic, pathological and clinical variables with MRI morphological scans, where different kinds of damage scores were defined, were analysed.</div></div><div><h3>Results</h3><div>The patientssmedian age was 8 years; the most frequent tumour was ependymoma (41%), and supratentorial (71%) was the prevalent site. All but 2 children (with germ cell tumours), had received surgery and 32 chemotherapy courses before irradiation. Ad-hoc scores for neurological deficits, endocrine alterations and structural abnormalities were created and applied. Patients with infratentorial tumours locations showed the highest score of neurological damage while endocrine alterations were more serious in patients with craniopharyngioma and germ cell tumours of the sellar region and ventricular system. The median number of damaged areas was equal to 2 for each child. Neurological deficit scores were not associated with hydrocephalus and surgery/ies received, unlike endocrine deficits. Tumour site, length of symptoms and endocrine alterations were found to be associated with cognitive impairment.</div></div><div><h3>Conclusion</h3><div>The pre-radiation evaluations highlighted that damages develop already prior to focal-RT. Specific scores may quantify damages that are generated by multiple factors that need to be considered over time after irradiation.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"43 ","pages":"Article 103872"},"PeriodicalIF":3.2,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144204097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RCR meetings","authors":"","doi":"10.1016/S0936-6555(25)00125-6","DOIUrl":"10.1016/S0936-6555(25)00125-6","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"42 ","pages":"Article 103870"},"PeriodicalIF":3.2,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paid MBP advert Advanced Educational Supervisor 210x280_01","authors":"","doi":"10.1016/j.clon.2025.103876","DOIUrl":"10.1016/j.clon.2025.103876","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"42 ","pages":"Article 103876"},"PeriodicalIF":3.2,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Data Quality in Retrospective Oncology Publications","authors":"K. Goel ,&nbsp;E.E. Laseinde ,&nbsp;M.F. Gensheimer","doi":"10.1016/j.clon.2025.103865","DOIUrl":"10.1016/j.clon.2025.103865","url":null,"abstract":"<div><h3>Aims</h3><div>Survival endpoints are the cornerstone of cancer research. Their accuracy depends on the quality of the data sources, and many sources of survival data, such as electronic medical records (EMRs), provide incomplete data. It is unknown how often retrospective studies in oncology journals report their survival data sources or use high-quality sources.</div></div><div><h3>Materials and Methods</h3><div>Retrospective studies that included survival as an endpoint and were published in nine oncology journals in 2001, 2011, and 2021 were included. For each paper, endpoint(s) and outcome data source(s) were extracted. Data sources were categorised as high quality, uncertain quality, or unknown. The primary outcome was the proportion of studies utilising a high-quality survival data source.</div></div><div><h3>Results</h3><div>Of 514 included papers, the most commonly reported endpoint was overall survival (OS, 80%), followed by progression-free survival (PFS) and disease-free survival; 14% did not report survival data source. All journals more often used uncertain-quality than high-quality data sources, but papers published in 2021 used more high-quality sources than those in 2001/2011 (26% vs 13%). In multivariable regression, radiation oncology papers were less likely to use high-quality data sources (p &lt; 0.001), but there was no association of data quality with impact factor.</div></div><div><h3>Conclusion</h3><div>Most studies used sources of uncertain quality, and higher impact-factor journals did not publish a higher proportion of studies with high-quality data sources, though there was improvement over time. This suggests a need to improve compliance with reporting guidelines and encourage researchers to use high-quality survival data sources.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"43 ","pages":"Article 103865"},"PeriodicalIF":3.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144184456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Lack of Access to Immunotherapy Medications on Survival of Lung Cancer Patients","authors":"A. Tfayli,&nbsp;L. El-Halabi,&nbsp;M.H. Hodroj,&nbsp;F. Rammal,&nbsp;A. Ghais,&nbsp;R. Tfayli,&nbsp;A. Bou Orm,&nbsp;M. Charafeddine","doi":"10.1016/j.clon.2025.103864","DOIUrl":"10.1016/j.clon.2025.103864","url":null,"abstract":"<div><h3>Aims</h3><div>Lung cancer is the leading cause of cancer-related deaths globally. With the great advancements in the treatment, the accessibility and availability of expensive treatments such as immunotherapy can be affected by economic factors. This research aims to examine how the economic crisis in Lebanon influenced the progression-free survival (PFS) of individuals with metastatic non-small cell lung cancer (NSCLC).</div></div><div><h3>Materials and Methods</h3><div>A retrospective study was conducted on 84 patients with stage IV NSCLC treated at a tertiary care center in Lebanon. Patients were divided into two groups based on their treatment period: a control group (January 2019- December 2020) and a crisis group (October 2021 - December 2022). Data on patient demographics, treatment regimens, dose densities, and PFS were collected and analysed.</div></div><div><h3>Results</h3><div>The control group had a median PFS of 11.11 months, compared to 8.40 months for the crisis group. More patients in the control had access to immunotherapy (46.9% versus 31.4%, p = 0.47). Importantly, patients who received less than 50% of the standard immunotherapy dose did not have a shorter PFS compared to those who received the full dose. Statistical analysis did not reveal a significant correlation between immunotherapy dose density and PFS (p = 0.107).</div></div><div><h3>Conclusion</h3><div>Access to immunotherapy medications in first line therapy of metastatic NSCLC has a clear impact on PFS. However, patients receiving lower doses of immune checkpoint inhibitors (ICIs) demonstrated a similar PFS compared to those receiving full doses, which challenges conventional dosing strategies and suggests that effective cancer treatment can be achieved with lower dosing regimens. These findings open the door for further investigation to explore the relationship between immunotherapy dose and PFS.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"43 ","pages":"Article 103864"},"PeriodicalIF":3.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144167786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Radiotherapy for Metastatic Cervical Cancer: A Real-World Study","authors":"X.B. Tang ,&nbsp;Y. Zhang ,&nbsp;S.S. Ma ,&nbsp;L. Jiang ,&nbsp;T. Gao ,&nbsp;L.Q. Wei ,&nbsp;Q.F. Huang ,&nbsp;Z.X. Yang ,&nbsp;W.Y. Li ,&nbsp;F. Wu","doi":"10.1016/j.clon.2025.103867","DOIUrl":"10.1016/j.clon.2025.103867","url":null,"abstract":"<div><h3>Aims</h3><div>Data on the efficacy of radiotherapy (RT) in metastatic cervical cancer (mCC) are limited. Herein, we evaluated the efficiency of RT for mCC.</div></div><div><h3>Materials and methods</h3><div>This is a retrospective cohort study. A total of 99 patients with mCC from April 2018 to April 2022 were treated with either radiotherapy group (RT group) or non-radiotherapy group (NRT group). All patients received systemic treatments.</div></div><div><h3>Results</h3><div>The complete response rates (CRRs) were 15.8% and 4.8% (<em>P =</em> 0.322) and the objective response rates (ORRs) were 68.4% and 42.8% (<em>P =</em> 0.011) in the RT group and NRT group, respectively. The median follow-up was 16 months (5–53 months). The RT group showed higher overall survival (OS) (1-year 82.5% vs 57.1%, 2-years 60.7% vs 31.1%, <em>P</em> = 0.035) and progression-free survival (PFS) (1-year 64.7% vs 35.7%, 2-years 41.3% vs 24.4%, <em>P</em> = 0.022). RT extended median OS (mOS) from 16 to 27 months and median PFS (mPFS) from 9 to 18 months. Multivariate analyses revealed radiotherapy, 5–8 chemotherapy cycles, and nonhepatic metastasis as independent prognostic factors for OS and PFS. Subgroup analysis showed improved OS and PFS with RT in patients aged over 60, with squamous cell carcinoma, single organ metastasis, and those receiving 2–4 chemotherapy cycles. Besides, notably, enhanced OS was observed in patients with lymph node-only metastasis who received RT (78.9% vs. 50.0%, <em>P</em> = 0.029). The primary acute adverse event was haematology toxicity. There was no increased toxicity with the addition of RT.</div></div><div><h3>Conclusion</h3><div>Radiotherapy combined with systemic therapy demonstrates an increased objective response rate for mCC. It can also improve OS and PFS and extend mOS and mPFS for mCC without escalating treatment-related toxicity. For patients aged over 60, with squamous cell carcinoma, single organ metastasis, lymph node-only metastasis, and those receiving 2–4 chemotherapy cycles, proactive RT intervention is recommended. Careful patient selection is advised for RT in mCC.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"43 ","pages":"Article 103867"},"PeriodicalIF":3.2,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144230968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}